A clinical-stage TIL therapy for solid tumors
AgonOx is a clinical-stage cancer immunotherapy company. Our lead program, AGX-148, is a selected, tumor-reactive CD8+ TIL therapy now in Phase 1, backed by a discovery pipeline of additional adoptive cell therapy programs.
